SK-7041: an antineoplastic agent; structure in first source
ID Source | ID |
---|---|
PubMed CID | 6918714 |
CHEMBL ID | 152133 |
SCHEMBL ID | 3360862 |
MeSH ID | M0481527 |
Synonym |
---|
sk-7041 |
in-2001 |
CHEMBL152133 , |
4-(dimethylamino)-n-[[4-[(e)-3-(hydroxyamino)-3-oxoprop-1-enyl]phenyl]methyl]benzamide |
SCHEMBL3360862 |
bdbm50474471 |
sk 7041 |
617690-98-9 |
in 2001 |
(e)-4-(dimethylamino)-n-(4-(3-(hydroxyamino)-3-oxoprop-1-en-1-yl)benzyl)benzamide |
4-dimethylamino-n-[4-(2-hydroxycarbamoylvinyl)benzyl]benzamide |
AKOS040746349 |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Histone deacetylase 3 | Homo sapiens (human) | IC50 (µMol) | 0.1720 | 0.0004 | 0.6196 | 10.0000 | AID316888 |
Histone deacetylase 4 | Homo sapiens (human) | IC50 (µMol) | 0.1720 | 0.0006 | 1.0526 | 10.0000 | AID316888 |
Histone deacetylase 1 | Homo sapiens (human) | IC50 (µMol) | 0.1720 | 0.0001 | 0.5543 | 9.9000 | AID316888 |
Histone deacetylase 7 | Homo sapiens (human) | IC50 (µMol) | 0.1720 | 0.0007 | 1.0260 | 9.9000 | AID316888 |
Histone deacetylase 2 | Homo sapiens (human) | IC50 (µMol) | 0.1720 | 0.0001 | 0.7221 | 9.9700 | AID316888 |
Polyamine deacetylase HDAC10 | Homo sapiens (human) | IC50 (µMol) | 0.1720 | 0.0005 | 0.7245 | 9.9000 | AID316888 |
Histone deacetylase 11 | Homo sapiens (human) | IC50 (µMol) | 0.1720 | 0.0003 | 0.9298 | 9.9000 | AID316888 |
Histone deacetylase 8 | Homo sapiens (human) | IC50 (µMol) | 0.1720 | 0.0007 | 0.9947 | 9.9000 | AID316888 |
Histone deacetylase 6 | Homo sapiens (human) | IC50 (µMol) | 0.1720 | 0.0000 | 0.5376 | 9.9000 | AID316888 |
Histone deacetylase 9 | Homo sapiens (human) | IC50 (µMol) | 0.1720 | 0.0005 | 0.9413 | 9.9000 | AID316888 |
Histone deacetylase 5 | Homo sapiens (human) | IC50 (µMol) | 0.1720 | 0.0007 | 0.9610 | 10.0000 | AID316888 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID316885 | Antiproliferative activity against human A549 cells | 2008 | Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6 | Histone deacetylase inhibitors: from bench to clinic. |
AID316893 | Inhibition of HDAC8 | 2008 | Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6 | Histone deacetylase inhibitors: from bench to clinic. |
AID106868 | Compound was tested for antiproliferative activity against human MKN45 cancer cell lines | 2003 | Journal of medicinal chemistry, Dec-18, Volume: 46, Issue:26 | Synthesis and biological evaluation of 3-(4-substituted-phenyl)-N-hydroxy-2-propenamides, a new class of histone deacetylase inhibitors. |
AID316945 | Inhibition of HDAC1 at 1 uM | 2008 | Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6 | Histone deacetylase inhibitors: from bench to clinic. |
AID316941 | Inhibition of HDAC9 | 2008 | Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6 | Histone deacetylase inhibitors: from bench to clinic. |
AID201624 | Compound was tested for antiproliferative activity against human SK-BR-3 cancer cell lines | 2003 | Journal of medicinal chemistry, Dec-18, Volume: 46, Issue:26 | Synthesis and biological evaluation of 3-(4-substituted-phenyl)-N-hydroxy-2-propenamides, a new class of histone deacetylase inhibitors. |
AID316947 | Inhibition of HDAC3 at 1 uM | 2008 | Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6 | Histone deacetylase inhibitors: from bench to clinic. |
AID316936 | Inhibition of HDAC7 | 2008 | Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6 | Histone deacetylase inhibitors: from bench to clinic. |
AID316886 | Antiproliferative activity against human SKBR3 cells | 2008 | Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6 | Histone deacetylase inhibitors: from bench to clinic. |
AID90349 | Inhibitory activity against Histone deacetylase (HDAC) from SNU-16 (human gastric adenocarcinoma) cells | 2003 | Journal of medicinal chemistry, Dec-18, Volume: 46, Issue:26 | Synthesis and biological evaluation of 3-(4-substituted-phenyl)-N-hydroxy-2-propenamides, a new class of histone deacetylase inhibitors. |
AID316948 | Inhibition of HDAC4 at 1 uM | 2008 | Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6 | Histone deacetylase inhibitors: from bench to clinic. |
AID316949 | Inhibition of HDAC5 at 1 uM | 2008 | Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6 | Histone deacetylase inhibitors: from bench to clinic. |
AID316887 | Antiproliferative activity against human MKN45 cells | 2008 | Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6 | Histone deacetylase inhibitors: from bench to clinic. |
AID316950 | Inhibition of HDAC6 at 1 uM | 2008 | Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6 | Histone deacetylase inhibitors: from bench to clinic. |
AID316946 | Inhibition of HDAC2 at 1 uM | 2008 | Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6 | Histone deacetylase inhibitors: from bench to clinic. |
AID8302 | Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay | 2003 | Journal of medicinal chemistry, Dec-18, Volume: 46, Issue:26 | Synthesis and biological evaluation of 3-(4-substituted-phenyl)-N-hydroxy-2-propenamides, a new class of histone deacetylase inhibitors. |
AID316888 | Inhibition of HDAC from human SNU16 cells | 2008 | Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6 | Histone deacetylase inhibitors: from bench to clinic. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 7 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.16) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 1 (12.50%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 7 (87.50%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |